Mylan Executive Chairman Robert J. Coury commented: "With these appointments, I am very pleased to continue to deliver on our objective of enhancing and strengthening Mylan at all levels, including its board of directors, as we seek to continue our exciting growth trajectory. Our entire board and I have been extremely impressed with Melina's deep knowledge of, and experience in, the financial markets, understanding of optimal corporate structures and track record of unleashing shareholder value during her career in private equity. Melina also brings Mylan deep market insights and relationships across the financial community. I am pleased to welcome Melina to the Mylan board of directors and look forward to benefiting from her contributions to the company."Rajiv Malik is currently Mylan's president, responsible for the company's operations, including oversight for research and development, business development, regulatory affairs, manufacturing operations and strategy, quality, supply chain, sourcing, packaging and medical affairs, as well as the sales and marketing of Mylan's generics business. Malik has held important leadership positions at Mylan since January 2007, when the company acquired a controlling stake in Matrix Laboratories Limited (now Mylan Laboratories Limited), one of the world's largest suppliers of active pharmaceutical ingredients. At the time of the acquisition, Malik was Matrix's chief executive officer. During his tenure at Mylan, Malik has played a key role in significantly expanding and diversifying Mylan's global product portfolio, pipeline and manufacturing footprint. In partnership with Mylan's leadership team, Malik played a significant role in leading the integrations of Mylan and Matrix and Mylan and the generics business of Merck KGaA to leverage the benefits of global scale and vertical and horizontal integration. Malik also is responsible for helping lead Mylan's expansion into emerging and other new commercial markets, such as the company's recent commercial launch in India, and he has helped establish Mylan as a leader in antiretroviral (ARV) medicines, particularly in developing markets. Malik has approximately 30 years of experience in the global generic pharmaceutical industry. Prior to joining Matrix in 2005, Malik was head of Global Development and Regulatory at Sandoz. He started his R&D career at Ranbaxy Laboratories, rising to head of Generics R&D. Malik earned his master's degree in pharmaceutical technology from Punjab University, India, and has more than 60 process patents to his credit. "I feel privileged and honored to be elevated to the Mylan board. Since joining Mylan following the acquisition of Matrix, I have felt like a part of the Mylan family, a feeling shared by many others who have joined me on this exciting journey over the past few years," said Malik. "I have had the opportunity to work closely with our passionate leadership team and talented people across the Mylan organization to build a strong foundation and help transform Mylan into a powerful global force in our industry. I am very excited about our very promising future and look forward to adding further value to my fellow board members, as well as the rest of the leadership team, in accomplishing Mylan's mission and achieving its strategic and financial objectives."